NCT07302464

Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

Effect of Sodium Glucose Co-Transporter 2 Inhibitors on Estimated Glomerular Filtration Rate in Diabetic Versus Non-Diabetic Chronic Kidney Disease Patients

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 60 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

The work aimed to compare the effects of Sodium-glucose co-transporter-2 (SGLT2) inhibitors on glomerular filtration rate (GFR) in patients with diabetic chronic kidney disease (CKD) and non-diabetic CKD.

Detailed description

Glucose reabsorption is mediated by the sodium-glucose cotransporter (SGLT) 2, which reabsorbs 90% of glucose, and SGLT1, which reabsorbs the remaining 10%. The relationship between hyperglycaemia and the development of renal disease is complex. Hyperglycaemia-induced complications are mediated by several metabolic pathways, among which accumulation of Advanced Glycation End-products with abnormalities of the glycosylation of macromolecules and increased glucose flux through the polyol pathway seem to be the most important.

Conditions

• Sodium Glucose Co-Transporter 2 Inhibitors
• Estimated Glomerular Filtration Rate
• Diabetes
• Chronic Kidney Disease

Interventions

Type	Name	Description
OTHER	Sodium Glucose Co-Transporter 2 Inhibitors	All candidates start therapy with sodium glucose co-transporter 2 (SGLT2) inhibitors with a dose of 10mg daily Dapagliflozin for 6 months

Timeline

• Start date: 2024-10-01
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2025-12-24
• Last updated: 2025-12-24

Locations

1 site across 1 country: Egypt